Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis - PubMed
6 hours ago
- #CETP inhibitors
- #High risk ASCVD
- #Lipid lowering therapy
- Obicetrapib, a CETP inhibitor, significantly improves lipid profiles in high-risk ASCVD patients.
- Key lipid improvements include reductions in LDL-C (-31.75%), non-HDL-C (-29.35%), and Lp(a) (-35.67%), with a notable increase in HDL-C (+125.94%).
- The treatment showed no significant increase in adverse events, including AKI, transaminase or CK elevation, and hypertension.
- Further long-term studies are needed to assess sustained efficacy, long-term safety, and impacts on cardiovascular outcomes.